Cardiac Troponins And The Cardiac Myocyte

Cardiovascular diseases has affected large number of population worldwide and in developed countries it is responsible for half of all deaths, coronary artery disease (CAD) alone is responsible for 1 of every 4.7 deaths in the United States (Eichner et al., 2002).

Based off of the case study regarding a 47 year old man who has recently been diagnosed with a heart disease known as CAD; I decided to further my research on this topic because it was intriguing to discover all heart diseases including coronary heart disease are taking the lives of countless individuals each year in our nation. A tremendous number of more than 13 million Americans (2005-2015, WebMD).

Troponin is present in heart muscle cells. If damage is done to these cells, it releases troponin into the bloodstream. The blood level of troponin, during a heart attack, increases within 3-12 hours from the onset of chest pain. It peaks between 24-48 hours and returns to a normal level over 5-14 days (Koutoukidis, Stainton & Hughson 2013, p. 506). The indicators include acute myocardial infarction, severe pulmonary embolism causing acute right heart overload, heart failure, and myocarditis. The normal value of Troponin I is <20

Heart failure (HF) is defined as a multifaceted clinical syndrome that can result from any structural or functional cardiac disorder that impairs the ability of the ventricle to fill with or eject blood. In HF, the heart may not provide tissues with adequate blood for metabolic needs, and cardiac-related elevation of pulmonary or systemic venous pressures may result in organ congestion1. In the United States, HF is increasing in incidence with about 5.1 million people suffering from HF and half of people who develop HF die within 5years 2. Over 75% of existing and new cases occurred in individuals over 65 years of age, < 1% in individuals below 60 years, nearly 10% in those over 80 years of age. HF costs the

Noyan, T., Gozlukaya, O., & Cankaya, S. (2013). The Evaluation of Cardiac TroponinI Assays Measured Radiometer AQT90 Flex and ReLIA Analyze

The results also showed that patients in the treatment group had a lower risk of hospitalization for heart failure, progression of albuminuria, and loss of kidney function

The leading cause of death among all dialysis patients is cardiac disease which all too often results in sudden cardiac arrest or sudden cardiac death. Sudden cardiac arrest or death is the consequence of fatal arrhythmias that result in the loss of cardiac function. According to the Cleveland Clinic, the most common life threatening arrhythmia is ventricular fibrillation. With these fatal

Research by the American Heart Association (2014) states that heart failure effects an estimated 5.1 million Americans and it is predicted to increase 25% by 2030. Heart failure is a pathophysiological condition that indicates the heart is unable to promote enough cardiac output causing insufficient blood supply to the body. Pharmacological treatment for cardiac failure is dependent upon the ability to decrease rate of blood flow and blood pressure. Survival after heart failure diagnosis has improved with medication but the death rate remains high with over half of the people diagnosed with heart failure will die within 5 years. (Go et al., 2014)

In the United States, over 5 million patients have heart failure (HF) and approximately 20 million patients have chronic kidney disease (CKD). Both conditions are linked by multiple risk factors including obesity, hypertension, diabetes mellitus, tobacco abuse, and increasing age. The presence of HF increases the risk of CKD and vice versa. Nearly one third of all patients with HF and 70% of Medicare patients with HF have Stage III CKD or greater and approximately 50% of dialysis dependent end stage renal disease (ESRD) patients will develop HF.

blood count indicates anemia due to decreased production of erythropoietin (Castner, 2010). A CT scan or MRI can evaluate the anatomy and function of the kidneys to help determine the cause and stage of the disease. A renal biopsy may also be performed. These diagnostic tests determine the progression of the disease. There are five stages of chronic kidney disease. The treatment plan depends on the stage of the disease. If it is diagnosed in stage one, the patient and physician can work to treat the contributing factors and slow the progression of the disease. By the fifth stage the patient is on dialysis, needs a transplant, or in the most severe cases is in hospice care (Castner, 2010).

Heart failure diagnoses are carried out by a specialized medical practitioner. It comprises of holistic patient health review such as patient medical history, patients symptoms, lungs con-gestion assessment, carrying out physical activity under observation, assessing for fluid re-tention (edema) and also assessing risk factors such as Coronary artery diseases, high blood pressure, Diabetes. According to tansy (2010 1399), heart failure can be diagnosed using different test methods such as Blood tests. This helps to check for any possible diseases in the thyroid, kidney or liver that can cause heart problems (NT-proBNP). N--terminal pro-B-type natriuretic peptide is a chemical checked in the blood. When the heart is under stress BNP is secreted

We used clinical and biochemical data derived from the DaVita database. The study population (N=420,255) included subjects undergoing hemodialysis in DaVita facilities across the US during the period of 2004 to 2011.

Blood tests will be done to assess troponin I, troponin T, creatine kinase (CK) and myoglobin which are classified as cardiac serum markers (Cardiac Emergencies, n.d.).

As the population ages heart failure is expected to increase exceptionally. About twenty-two percent of men and forty-four percent of women will develop heart failure within six years of having a heart attack. “Thirty years ago patients would have died from their heart attacks!” (Couzens)

causes it is associated with increased mortality. It is estimated that 4,270 patients die from kidney